These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23285908)

  • 21. [Construction of evaluation systems for traditional Chinese medicine multiple drug delivery system on basis of component level].
    Yu DH; Liu D; Jia XB; Sun E; Zhang ZH; Xiao W
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(17):2667-71. PubMed ID: 23236774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Some issues to notice in the research and quality evaluation of external preparations of traditional Chinese medicine].
    Jin F
    Zhongguo Zhong Yao Za Zhi; 2010 Nov; 35(21):2934-6. PubMed ID: 21322963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transparently reporting adverse effects of traditional Chinese medicine interventions in randomized controlled trials.
    Cheng CW; Bian ZX; Li YP; Moher D; Wu TX; Dagenais S; Li J; Li TQ
    Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):881-6. PubMed ID: 18782527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].
    Shang HC; Zhang BL; Li YP
    Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse drug reactions and adverse events of 33 varieties of traditional Chinese medicine injections on National Essential medicines List (2004 edition) of China: an overview on published literatures.
    Wang L; Yuan Q; Marshall G; Cui X; Cheng L; Li Y; Shang H; Zhang B; Li Y
    J Evid Based Med; 2010 May; 3(2):95-104. PubMed ID: 21349051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
    Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison and analysis of clinical safety evaluation methods for parenterally administered Chinese medicine].
    Yan BH; Peng C; Xie YM; Wang YY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2979-82. PubMed ID: 24471315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommendations for reporting adverse drug reactions and adverse events of traditional Chinese medicine.
    Wu T; Shang H; Bian Z; Zhang J; Li T; Li Y; Zhang B
    J Evid Based Med; 2010 Feb; 3(1):11-7. PubMed ID: 21349035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Protocol of intensive hospital monitoring with long follow up and large sample: Diemailing Kudiezi injection as example].
    Liao X; Xie YM; Wang GQ
    Zhongguo Zhong Yao Za Zhi; 2016 Dec; 41(24):4494-4499. PubMed ID: 28936829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicological risks of Chinese herbs.
    Shaw D
    Planta Med; 2010 Dec; 76(17):2012-8. PubMed ID: 21077025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis on reasons for disapproval of registration application of new traditional Chinese medicines in recent years].
    Zhang X; Zhang L; Wang H
    Zhongguo Zhong Yao Za Zhi; 2012 Aug; 37(15):2333-7. PubMed ID: 23193572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Thought on several problems of post-marketing herbs clinical evaluation in special populations].
    Zhou A; Lian F
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2776-8. PubMed ID: 22292362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Application of traditional Chinese medicine injections using traditional Chinese medicine theory].
    Han W; He E; Cao J
    Zhongguo Zhong Yao Za Zhi; 2012 Aug; 37(16):2498-500. PubMed ID: 23234156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Causes and countermeasures about adverse reaction of traditional Chinese medicine].
    Wang Q; Li H; Zhang Z
    Zhong Yao Cai; 2001 Jun; 24(6):430-3. PubMed ID: 11563192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Regional development of patents of traditional Chinese medicine compounds on basis of cluster analysis].
    Yang X; Xiao S
    Zhongguo Zhong Yao Za Zhi; 2012 Aug; 37(16):2472-7. PubMed ID: 23234153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Principle of adverse drug reaction causality judgement and interpretation of causality assessment method both in China and abroad].
    Wei X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2744-7. PubMed ID: 23285925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Enlightenment of adverse reaction monitoring on safety evaluation of traditional Chinese medicines].
    Song HB; Du XX; Ren JT; Yang L; Guo XX; Pang Y
    Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1620-3. PubMed ID: 26281610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacovigilance of medicinal products in Poland--new guidelines].
    Jabłecka A; Korzeniowska K; Balcer-Dymel N
    Przegl Lek; 2012; 69(10):1127-8. PubMed ID: 23421106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Technical specifications for rational clinical use of parenterally administered Chinese medicine (draft version for comments)].
    Xie YM; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Zhao YB
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2930-2. PubMed ID: 24471306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Preliminary study on general regulations for processing of different processing procedures of prepared slices of Chinese crude drugs in China].
    Huang QW; Li H; Huang XJ; Yu JY
    Zhongguo Zhong Yao Za Zhi; 2014 Jan; 39(1):153-6. PubMed ID: 24754186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.